Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of CR845 in chronic kidney disease patients with moderate-to-severe pruritus has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Pruritus

Drugs mentioned

• CR845 (difelikefalin)

Snippet

Sponsor: Cara Therapeutics, Inc. | Conditions: Chronic Kidney Diseases, Pruritus | Phase 2 | Status: COMPLETED | Results posted: 2024-01-24